Reuters: Regulatory News: UPDATE 1-FDA adds warnings to Forest Labs' Celexa label

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-FDA adds warnings to Forest Labs' Celexa label Mar 28th 2012, 12:12 March 28 | Wed Mar 28, 2012 8:12am EDT March 28 (Reuters) - U.S. health regulators added new warnings to the label of Forest Laboratories Inc's antidepressant Celexa and its generic versions about a potential risk of rare heart diseases. The changed drug label has a particular caution for patients with certain conditions because of the risk of QT syndrome -- a disorder of the heart's electrical activity. The FDA also said the maximum recommended dose of Celexa, or citalopram, is 20 mg per day for patients older than 60 years.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions